SUZHOU, Chine et MÖLNDAL, Suède, 9 octobre 2026 /PRNewswire/ -- Suzhou Ribo Life Science (06938.HK) et sa filiale Ribocure Pharmaceuticals AB (désignées collectivement sous le nom de « Ribo ») ont annoncé avoir déposé une demande d'essai clinique de phase I (CTA) auprès de l'Union...
Hence then, the article about ribo soumet une demande d essai clinique europeen pour une etude de phase i pour l arnsi rbd3133 ciblant l inhbe was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Ribo soumet une demande d'essai clinique européen pour une étude de phase I pour l'ARNsi RBD3133 ciblant l'INHBE )
Also on site :
- Steven R. McQueen Sends Direct Message in First Social Media Selfie in 5 Years After Rare Public Return Sparks Buzz Over His Changed Appearance
- Why ‘You Can See Everything Everything’ Could Make Oscars History as First Doc Nominated for Best Picture
- What were Trump operatives doing for pro-Russian politician Dodik in Bosnia?